Trial record 4 of 143 for:    caregiving

Coordinating Center for Enhancing ADRD Caregiving

This study has been completed.
Sponsor:
Collaborators:
Information provided by:
University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT00178165
First received: September 13, 2005
Last updated: NA
Last verified: September 2005
History: No changes posted
  Purpose

Established in 1995, Resources for Enhancing Alzheimer's Caregiver Health (REACH) is a unique, multi-site research program sponsored by the National Institute on Aging (NIA) and the National Institute on Nursing Research (NINR). The primary purpose of REACH is to carry out social and behavioral research on interventions designed to enhance family caregiving for Alzheimer's disease and related disorders. Specifically, REACH has two goals: to test the effectiveness of multiple different interventions and to evaluate the pooled effect of REACH interventions overall. REACH grew out of a National Institute of Health (NIH) initiative that acknowledged the well-documented burdens associated with family caregiving as well as the existence of promising family caregiver interventions reported in the literature.


Condition Intervention
Dementia
Alzheimer Disease
Procedure: Skill Training Condition – problem solving training
Procedure: REACH for TLC (Telephone Linked Computer) system

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Coordinating Center for Enhancing Alzheimer Disease and Related Disorder Caregiving

Resource links provided by NLM:


Further study details as provided by University of Pittsburgh:

Primary Outcome Measures:
  • The outcomes were assessed 6 months after randomization and included a measure of burden and a measure of depression. Caregiver burden was assessed using the Revised Memory and Behavior Problem Checklist (RMBPC).
  • Emotional distress was determined by the Center for Epidemiological Studies Depression Scale (CES-D) a global measure of depression.

Secondary Outcome Measures:
  • Long-term care placement of dementia patients and caregiver health and well-being
  • Use of cognitive enhancement medication
  • Clinical significance of caregiver interventions in diverse populations

Estimated Enrollment: 1200
Study Start Date: September 1996
Estimated Study Completion Date: November 2001
Detailed Description:

Six sites (Boston, Birmingham, Memphis, Miami, Palo Alto, and Philadelphia) developed and evaluated a variety of multi-component interventions for family caregivers of persons with Alzheimer’s Disease (AD) at the mild or moderate level of impairment. The multi-component interventions implemented across the six sites included: 1) Individual Information and Support strategies, 2) Group Support and Family Systems therapy, 3) Psychoeducational and Skill-based Training approaches, 4) Home-based Environmental interventions,, and 5) Enhanced Technology Support Systems. Although the interventions were derived from diverse theoretical models, they are all consistent with basic health-stress models in which the goal is to change the nature of specific stressors (e.g. problem behavior of the care recipient), their appraisal, and/or the caregivers response to the stressors. All of the REACH interventions were guided by detailed treatment manuals and certification procedures that assured that the interventions were delivered consistently over time at each site. Careful attention was also paid to the issue of treatment integrity. Different strategies were used at each site to induce and assess all three fundamental aspects of treatment integrity: delivery, receipt, and enactment (Burgio, et al., 2001). In addition, because the caregiving experience in race and ethnic minority families is particularly neglected in the field, there was a strong emphasis placed on the inclusion of African American and Hispanic caregivers. Thus, assessments as well as interventions were tailored at each site to meet the needs of culturally diverse racial/ethnic majority and minority populations.

All of the REACH sites shared several common goals, including: 1) designing theory-driven caregiving interventions to test hypotheses about intervention processes and their effect on family caregivers, 2) specifying intervention components that help us understand the pathways through which interventions produce desired outcomes, 3) developing a standardized outcome protocol to assess the impact of different strategies on caregivers and their care recipients within each site and across sites, and 4) creating a common database that would facilitate pooling data across sites. In addition, standard selection criteria were adopted by REACH.

Although REACH has some of the features of a traditional multi-site randomized controlled clinical trial (e.g., random assignment of participants to treatment and control conditions, common database and outcome measures, and identical measurement intervals across sites), it differs on one key dimension—the interventions varied across sites. REACH was designed to examine the feasibility and outcomes of multiple different intervention approaches, rather than to provide definitive information on the efficacy of one specific intervention strategy for enhancing caregiver outcomes. The strength of this approach is that it efficiently yields information about the effectiveness of different approaches to AD caregiving as well as the combined effects of active treatment versus controls, as reported in the planned meta-analysis.

REACH successfully randomized 1222 caregiver/care recipient dyads representing both majority and minority populations to 15 different conditions.

  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

CORE CARE RECIPIENT INCLUSION/EXCLUSION CRITERIA

Inclusion criteria:

  1. NINCDS -ADRDA Criteria for Alzheimer’s Disease and/or DSM IV Criteria for Alzheimer’s Disease or other dementia or MMSE score < 23.
  2. Functional impairment: presence of two IADL or one ADL impairments.

Exclusion criteria:

  1. Any terminal illness with life expectancy < 6 months
  2. Active treatment (chemotherapy, radiation therapy) for cancer
  3. More than three acute medical hospitalizations in past year (not for psychiatric or Alzheimer’s Disease related admission)
  4. Schizophrenia (onset of delusions before age 45)
  5. Dementia secondary to head trauma (probable)
  6. Blindness or deafness if either disability prohibits them from completion of data collection or participation in the interventions
  7. MMSE = 0 and bedbound (confined to a bed or chair for > 22 hours per day, for at least 4 of the past 7 days)
  8. Planned nursing home admission in 6 months

CORE CAREGIVER INCLUSION/EXCLUSION CRITERIA

Inclusion criteria:

  1. Age: 21 years and older
  2. Language: site specific, must be competent either orally or written
  3. Lives with care recipient
  4. Family member
  5. Gender: Palo Alto/Los Angeles will only enroll women. All other sites will enroll men and women
  6. Must have a telephone
  7. At enrollment, plan to remain in area for the duration of the intervention and follow-up
  8. Caregiver role of at least 6 months
  9. Provides > 4 hours of supervision or direct assistance per day for the care recipient

Exclusion criteria:

  1. Any terminal illness with life expectancy < 6 months
  2. Active treatment (chemotherapy, radiation therapy) for cancer
  3. More than three acute medical hospitalizations in past year
  4. Involved in another clinical trial of interventions for caregivers (non drug study)

Second Level Review If the caregiver has been inconsistent with answers or repeated answers, then the interviewer will administer the SPMSQ. The interviewer will then discuss with the PI and coordinate another phone call with the caregiver.

If in the course of the telephone screen the research assistant believes that there may be difficulties for the caregiver regarding travel arrangements, hesitancy to answer questions, or other specific items (site-specific indications), the research assistant will refer to the PI for review.

All potential caregivers will receive a follow-up phone call for second level exclusion from the trial when appropriate.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00178165

Locations
United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294-2041
United States, California
Stanford University and Veterans Affairs
Menlo Park, California, United States, 94025
United States, Florida
University of Miami at Miami, Center on Adult Development and Aging
Miami, Florida, United States, 33136
United States, Pennsylvania
Thomas Jefferson University at Philadelphia, Center for Applied Research on Aging and Health
Philadelphia, Pennsylvania, United States, 19107
United States, Tennessee
University of Tennessee Health Science Center
Memphis, Tennessee, United States, 38163
Sponsors and Collaborators
University of Pittsburgh
Investigators
Principal Investigator: Richard Schulz, Ph.D. Professor of Psychiatry and Director, University Center for Social and Urban Research, University of Pittsburgh
  More Information

Publications:

ClinicalTrials.gov Identifier: NCT00178165     History of Changes
Other Study ID Numbers: AG13305-01, NR13269, AG13313, AG13297, AG13289, AG13265, AG13255, AG13305
Study First Received: September 13, 2005
Last Updated: September 13, 2005
Health Authority: United States: Federal Government

Keywords provided by University of Pittsburgh:
Family Caregivers
Dementia
Alzheimer Disease
Randomized Controlled Trial
Intervention Studies

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders

ClinicalTrials.gov processed this record on September 30, 2014